Insights on Deucravacitinib for Psoriasis During Expert Consensus Panel, with Hassan Hamade, MD

Following the conclusion of a recent expert consensus panel—the results of which were published in the Journal of Drugs in Dermatology—clinical recommendations on the use of deucravacitinib in psoriasis management were released.1

This panel’s findings, highlighted in a recent interview published by HCPLive, were also discussed by one of the panelists: Hassan Hamade, MD, from the Icahn School of Medicine at Mount Sinai.2 Hamade spoke with HCPLive about the expert consensus panel, highlighting what the findings impacted as far as his own thinking about deucravacitinib.1

“More than anything, it was the re-emphasis on who would benefit from a small molecule inhibitor,” Hamade explained. “Of course, it doesn't hurt to emphasize that the safety profile is fantastic and that there will be many patients where this is not only a great standalone but also a great adjunct. I think, more than anything, the reminder of it being used as an adjunct for patients with incomplete therapy is great. You have patients on regular biologics, and if you need to give them that extra ‘oomph,’ this is a very safe way to do so, with clear efficacy and clear safety boundaries.”

Hamade was also asked if any of the real-world evidence or patient-reported outcomes around deucravacitinib resonated with his own experience managing psoriasis.

“The patient report outcomes are consistent with what we saw between trials and my own patients,” Hamade said. “We definitely see patients who are fairly happy with the medication, with their quality of life improving in many different outcomes. Even if we like trials to look at very hard metrics, there are softer metrics that are just as important to patients' quality of life. These really stand out with how the patients were feeling. Pills are always easier than an injection, and that's what you're doing with deucravacitinib. Beyond that, patients will tell you they have less itch, less pain, and they're sleeping better. These are all things that are not primary endpoints, but are fundamental to the patient experience and their overall well-being.”

For any additional information on deucravacitinib’s use in psoriasis, view the full interview segment with Hamade posted above.

The quotes contained in this summary were edited for clarity.

References

1. Shah M, Burshtein J, Lebwohl M, et al. A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel. J Drugs Dermatol. 2025 Feb 1;24(2):147-155. doi: 10.36849/JDD.8616. PMID: 39913225.

2. Shah M. Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD. HCPLive. June 13, 2025. Accessed July 16, 2025. https://www.hcplive.com/view/efficacy-safety-deucravacitinib-psoriasis-milaan-shah-md.